Saturday, March 13, 2010
Quick Finacial Data
Advaxis Inc. Form 10k Filed 2010-02-19 link - http://secwatch.com/filings/view.jsp?formid=7039487&source=api
Income Statement Snapshot
Income Statement Snapshot
| View: Annual Data | Quarterly Data | All numbers in thousands |
| PERIOD ENDING | 31-Oct-09 | 31-Oct-08 | 31-Oct-07 | ||
| Total Revenue | 30 | 66 | 154 | ||
| Cost of Revenue | - | - | - | ||
| Gross Profit | 30 | 66 | 154 | ||
| Operating Expenses | |||||
| Research Development | 2,316 | 2,482 | 2,128 | ||
| Selling General and Administrative | 2,701 | 3,036 | 2,629 | ||
| Non Recurring | - | - | - | ||
| Others | - | - | - | ||
| Total Operating Expenses | - | - | - | ||
| Operating Income or Loss | (4,987) | (5,452) | (4,603) | ||
| Income from Continuing Operations | |||||
| Total Other Income/Expenses Net | 5,845 | 47 | 2,756 | ||
| Earnings Before Interest And Taxes | 858 | (5,405) | (1,847) | ||
| Interest Expense | 851 | 11 | 607 | ||
| Income Before Tax | 7 | (5,416) | (2,454) | ||
| Income Tax Expense | (922) | - | - | ||
| Minority Interest | - | - | - | ||
| Net Income From Continuing Ops | 929 | (5,416) | (2,454) | ||
| Non-recurring Events | |||||
| Discontinued Operations | - | - | - | ||
| Extraordinary Items | - | - | - | ||
| Effect Of Accounting Changes | - | - | - | ||
| Other Items | - | - | - | ||
| Net Income | 929 | (5,416) | (2,454) | ||
| Preferred Stock And Other Adjustments | - | - | - | ||
| Net Income Applicable To Common Shares | $929 | ($5,416) | ($2,454) | ||
Advaxis Develops Room Temperature Formulation of ADXS11-001
03/10/10- News Wire
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.
Advaxis has been investigating other methods for preserving its live vaccines without the need for freezing. Although live Listeria can be freeze dried, this method is associated with a loss of 90% or more of the bacterial activity. A recent test of a different method, called “foam drying” has delivered a product, which is stable at room temperature. Recovery of almost 100% of the product was observed and excellent biological activity was seen.
“This exciting work can make it possible to distribute our products to every physician’s office without special equipment using a low cost process,” commented Advaxis Chairman/CEO Thomas A. Moore. “It will be key to the licensing and commercialization of all our vaccine technologies.”
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.
Advaxis has been investigating other methods for preserving its live vaccines without the need for freezing. Although live Listeria can be freeze dried, this method is associated with a loss of 90% or more of the bacterial activity. A recent test of a different method, called “foam drying” has delivered a product, which is stable at room temperature. Recovery of almost 100% of the product was observed and excellent biological activity was seen.
“This exciting work can make it possible to distribute our products to every physician’s office without special equipment using a low cost process,” commented Advaxis Chairman/CEO Thomas A. Moore. “It will be key to the licensing and commercialization of all our vaccine technologies.”
Tuesday, March 2, 2010
Advaxis Management Discusses FY2009 on Results Call
For information about the results call: Telephone: Dial-in number: (218) 862-6403 | Access Code: 198209 Playback available until June 25, 2010 until 1800 EST
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, conducted its fiscal year end results conference call yesterday. Following is a summary
- Efforts to maximize shareholder value by demonstrating safety and efficacy of Advaxis’ lead, drug candidate ADXS11-001 – the overall development program for the Company’s proprietary live, attenuated Listeria immunotherapeutic agents for the treatment of cancer and infectious diseases
- Efforts to complete construct licensing post Phase II research, which may result in earlier capital returns
- Lowering corporate risk and maintaining corporate focus through strategic collaborations with recognized sites of excellence such as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute (NCI), the University of Pittsburgh and Cancer Research – UK (CRUK)
- Pre-clinical development of ADXS31-142 (prostate cancer construct) and ADXS31-164 (breast cancer construct) is close to completion and identification of academic clinical partners to initiate Phase I studies for both agents has begun
- Currently announced Advaxis clinical trials will have approximately 350 patients receiving in the aggregate with a overall cost to the Company of about $10 million
- Available funding includes more than $3.5 million in cash of the agreed upon $5.0 million funding instrument with Optimus Life Science Capital Partners, announced in June 2009
- The current short-term debt program in its final weeks; whereby, approximately $3.4 million was raised and roughly $900,000 repaid, with interest, to the debt holders.
Subscribe to:
Posts (Atom)